Taro must face US antitrust claims over generics, states argue
MLex Summary: US states accusing Taro Pharmaceuticals of artificially inflating generic drug prices and reducing competition told a federal judge that a private class action settlement does not bar their claims....To view the full article, register now.
Already a subscriber? Click here to view full article